Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07528053) titled 'A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants' on April 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.
Condition:
HV
Intervention:
Drug: BW-20805
Drug: BW-20805
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: April 28, 2026
Target Sample Size: 24
Countries of Recruitment:
Australia
To know more, visit https://clinicaltrials.gov/study/NCT07528053
Disclaimer: Curated by HT Syndi...